Symbols / TLSA Stock $1.12 -3.45% Tiziana Life Sciences Ltd

Healthcare • Biotechnology • United Kingdom • NCM
TLSA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Ivor R. Elrifi Ph.D.
Exch · Country NCM · United Kingdom
Market Cap 142.53M
Enterprise Value 131.41M
Income -18.43M
Sales —
FCF (ttm) -5.48M
Book/sh 0.08
Cash/sh 0.03
Employees 10
Insider 10d —
IPO Nov 20, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.61
PEG —
P/S —
P/B 14.55
P/C —
EV/EBITDA -6.22
EV/Sales —
Quick Ratio 0.72
Current Ratio 0.76
Debt/Eq 876.92
LT Debt/Eq —
EPS (ttm) -0.16
EPS next Y -0.20
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2022-12-27
Earnings (prior) 2022-12-27
ROA -115.96%
ROE -9.24%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 127.26M
Shs Float 63.89M
Insider Own 43.48%
Instit Own 2.94%
Short Float 4.02%
Short Ratio 6.18
Short Interest 1.46M
52W High 2.60
vs 52W High -56.92%
52W Low 1.04
vs 52W Low 7.69%
Beta 0.42
Impl. Vol. 50.00%
Rel Volume 0.35
Avg Volume 206.93K
Volume 73.18K
Target (mean) $8.86
Tgt Median $8.86
Tgt Low $8.86
Tgt High $8.86
# Analysts 1
Recom None
Prev Close $1.16
Price $1.12
Change -3.45%
About

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.86
Mean price target
2. Current target
$1.12
Latest analyst target
3. DCF / Fair value
$-0.77
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.12
Low
$8.86
High
$8.86
Mean
$8.86

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2022-06-13 init ThinkEquity — → Buy $4
News
RSS: Latest TLSA news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Cost Of Revenue
—
—
—
—
Reconciled Cost Of Revenue
—
—
—
—
Gross Profit
—
—
—
—
Operating Expense
21.13
+33.80%
15.79
-12.18%
17.98
+23.30%
14.59
Research And Development
10.28
+96.58%
5.23
-35.55%
8.11
-37.38%
12.96
Selling General And Administration
—
—
0.00
0.00
General And Administrative Expense
—
—
—
—
Salaries And Wages
—
—
0.00
0.00
Other Operating Expenses
10.85
+2.73%
10.56
+7.03%
9.87
+505.21%
1.63
Total Expenses
21.13
+33.80%
15.79
-12.18%
17.98
+23.30%
14.59
Operating Income
-21.13
-33.80%
-15.79
+12.18%
-17.98
-23.30%
-14.59
Total Operating Income As Reported
-21.13
-33.80%
-15.79
+12.18%
-17.98
-23.30%
-14.59
EBITDA
-18.18
-9.41%
-16.62
+3.03%
-17.14
-11.94%
-15.31
Normalized EBITDA
-20.88
-40.54%
-14.86
+11.22%
-16.73
-15.89%
-14.44
Reconciled Depreciation
0.23
+88.71%
0.12
+29.17%
0.10
+88.24%
0.05
EBIT
-18.41
-9.99%
-16.74
+2.86%
-17.23
-12.19%
-15.36
Total Unusual Items
2.70
+253.41%
-1.76
-337.81%
-0.40
+53.74%
-0.87
Total Unusual Items Excluding Goodwill
2.70
+253.41%
-1.76
-337.81%
-0.40
+53.74%
-0.87
Special Income Charges
—
—
—
0.00
Write Off
—
—
—
0.00
Net Income
-18.43
-55.37%
-11.86
+32.94%
-17.69
-14.90%
-15.40
Pretax Income
-18.43
-10.06%
-16.75
+2.88%
-17.24
-11.98%
-15.40
Net Non Operating Interest Income Expense
0.00
-99.88%
0.81
-29.37%
1.14
+19166.67%
-0.01
Interest Expense Non Operating
0.02
+200.00%
0.01
-40.00%
0.01
-73.68%
0.04
Net Interest Income
0.00
-99.88%
0.81
-29.37%
1.14
+19166.67%
-0.01
Interest Expense
0.02
+200.00%
0.01
-40.00%
0.01
-73.68%
0.04
Interest Income Non Operating
0.02
-97.67%
0.81
-29.46%
1.15
+3506.25%
0.03
Interest Income
0.02
-97.67%
0.81
-29.46%
1.15
+3506.25%
0.03
Other Income Expense
2.70
+253.41%
-1.76
-337.81%
-0.40
+50.00%
-0.80
Other Non Operating Income Expenses
—
—
—
0.07
Gain On Sale Of Security
2.70
+253.41%
-1.76
-337.81%
-0.40
+53.74%
-0.87
Tax Provision
0.00
+100.00%
-4.88
-1187.53%
0.45
0.00
Tax Rate For Calcs
0.00
-100.00%
0.00
+38.85%
0.00
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-0.51
-507.92%
-0.08
0.00
Net Income Including Noncontrolling Interests
-18.43
-55.37%
-11.86
+32.94%
-17.69
-14.90%
-15.40
Net Income From Continuing Operation Net Minority Interest
-18.43
-55.37%
-11.86
+32.94%
-17.69
-14.90%
-15.40
Net Income From Continuing And Discontinued Operation
-18.43
-55.37%
-11.86
+32.94%
-17.69
-14.90%
-15.40
Net Income Continuous Operations
-18.43
-55.37%
-11.86
+32.94%
-17.69
-14.90%
-15.40
Normalized Income
-21.13
-99.04%
-10.62
+38.89%
-17.37
-19.59%
-14.53
Net Income Common Stockholders
-18.43
-55.37%
-11.86
+32.94%
-17.69
-14.90%
-15.40
Diluted EPS
-0.16
-45.45%
-0.11
+35.29%
-0.17
-13.33%
-0.15
Basic EPS
-0.16
-45.45%
-0.11
+35.29%
-0.17
-13.33%
-0.15
Basic Average Shares
118.28
+10.88%
106.67
+4.10%
102.47
+0.93%
101.53
Diluted Average Shares
118.28
+10.88%
106.67
+4.10%
102.47
+0.93%
101.53
Diluted NI Availto Com Stockholders
-18.43
-55.37%
-11.86
+32.94%
-17.69
-14.90%
-15.40
Gain On Sale Of PPE
—
—
—
0.00
Line Item Trend 2024-12-31 2023-12-31 2022-12-31
Total Assets
11.28
-7.39%
12.18
-53.98%
26.48
Current Assets
7.51
+2.33%
7.34
-69.78%
24.28
Cash Cash Equivalents And Short Term Investments
3.72
+214.79%
1.18
-93.47%
18.12
Cash And Cash Equivalents
3.72
+214.79%
1.18
-93.47%
18.12
Receivables
3.69
-39.00%
6.05
+1.04%
5.99
Other Receivables
0.05
-56.20%
0.12
-6.92%
0.13
Taxes Receivable
0.03
-99.16%
3.79
-10.67%
4.25
Prepaid Assets
0.09
-9.80%
0.10
-40.00%
0.17
Hedging Assets Current
—
—
—
Total Non Current Assets
3.78
-22.10%
4.85
+120.82%
2.19
Net PPE
0.19
-36.18%
0.29
-24.68%
0.39
Gross PPE
0.19
-36.18%
0.29
-24.68%
0.39
Accumulated Depreciation
—
—
—
Machinery Furniture Equipment
—
—
—
Other Properties
0.19
-36.18%
0.29
-24.68%
0.39
Goodwill And Other Intangible Assets
—
0.00
0.00
Investments And Advances
3.59
-21.19%
4.55
+152.16%
1.81
Long Term Equity Investment
3.59
-21.19%
4.55
+152.16%
1.81
Non Current Accounts Receivable
—
—
—
Total Liabilities Net Minority Interest
7.35
+10.53%
6.65
-3.74%
6.91
Current Liabilities
7.35
+12.37%
6.54
-1.86%
6.66
Payables And Accrued Expenses
7.23
+13.20%
6.39
-2.22%
6.53
Payables
5.58
+34.88%
4.14
-16.63%
4.96
Accounts Payable
5.58
+34.88%
4.14
-16.63%
4.96
Current Accrued Expenses
1.65
-26.67%
2.25
+43.31%
1.57
Current Debt And Capital Lease Obligation
0.11
-23.19%
0.14
+13.11%
0.12
Current Capital Lease Obligation
0.11
-23.19%
0.14
+13.11%
0.12
Current Deferred Liabilities
0.00
—
—
Current Deferred Revenue
0.00
—
—
Other Current Liabilities
0.01
-14.29%
0.01
+55.56%
0.01
Total Non Current Liabilities Net Minority Interest
0.00
-100.00%
0.11
-55.14%
0.24
Long Term Debt And Capital Lease Obligation
0.00
-100.00%
0.11
-55.14%
0.24
Long Term Capital Lease Obligation
0.00
-100.00%
0.11
-55.14%
0.24
Stockholders Equity
3.94
-28.90%
5.54
-71.71%
19.57
Common Stock Equity
3.94
-28.90%
5.54
-71.71%
19.57
Capital Stock
0.11
+7.77%
0.10
+0.98%
0.10
Common Stock
0.11
+7.77%
0.10
+0.98%
0.10
Share Issued
111.46
+8.12%
103.09
+0.80%
102.27
Ordinary Shares Number
111.46
+9.80%
101.51
+0.92%
100.59
Treasury Shares Number
0.00
-100.00%
1.57
-6.54%
1.68
Additional Paid In Capital
23.11
+40.10%
16.49
+5.75%
15.60
Retained Earnings
-144.83
-8.34%
-133.68
-14.98%
-116.26
Gains Losses Not Affecting Retained Earnings
116.99
-0.06%
117.06
+1.29%
115.57
Treasury Stock
0.00
-100.00%
1.57
+19.24%
1.32
Other Equity Adjustments
118.70
+0.00%
118.70
+0.00%
118.70
Total Equity Gross Minority Interest
3.94
-28.90%
5.54
-71.71%
19.57
Total Capitalization
3.94
-28.90%
5.54
-71.71%
19.57
Working Capital
0.16
-79.95%
0.80
-95.47%
17.62
Invested Capital
3.94
-28.90%
5.54
-71.71%
19.57
Total Debt
0.11
-57.09%
0.25
-32.33%
0.36
Capital Lease Obligations
0.11
-57.09%
0.25
-32.33%
0.36
Net Tangible Assets
3.94
-28.90%
5.54
-71.71%
19.57
Tangible Book Value
3.94
-28.90%
5.54
-71.71%
19.57
Duefrom Related Parties Current
3.61
+68.71%
2.14
+32.47%
1.61
Dueto Related Parties Current
—
—
0.00
Foreign Currency Translation Adjustments
-1.71
-4.34%
-1.64
+47.70%
-3.13
Other Equity Interest
8.56
+20.07%
7.13
+21.11%
5.89
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-12.85
-741.87%
-1.53
+90.28%
-15.70
+19.97%
-19.61
Cash Flow From Continuing Operating Activities
-12.85
-741.87%
-1.53
+90.28%
-15.70
+19.97%
-19.61
Net Income From Continuing Operations
-18.43
-10.06%
-16.75
+2.88%
-17.24
-11.98%
-15.40
Depreciation Amortization Depletion
0.23
+88.71%
0.12
+29.17%
0.10
+88.24%
0.05
Depreciation
0.23
+88.71%
0.12
+29.17%
0.10
+88.24%
0.05
Depreciation And Amortization
0.23
+88.71%
0.12
+29.17%
0.10
+88.24%
0.05
Other Non Cash Items
3.13
-11.09%
3.52
+662.56%
-0.62
—
Stock Based Compensation
1.14
-20.15%
1.43
-17.59%
1.73
+222.98%
-1.41
Asset Impairment Charge
—
—
—
0.00
Operating Gains Losses
-0.15
-195.60%
0.16
-89.53%
1.52
+149.74%
-3.05
Unrealized Gain Loss On Investment Securities
-1.75
-199.55%
1.76
+337.81%
0.40
-53.74%
0.87
Net Foreign Currency Exchange Gain Loss
-0.15
-196.20%
0.16
-89.60%
1.52
+147.72%
-3.18
Gain Loss On Sale Of PPE
—
—
0.00
0.00
Change In Working Capital
3.06
+654.71%
-0.55
+65.11%
-1.58
-35.91%
-1.16
Change In Receivables
-0.38
+74.27%
-1.47
+3.61%
-1.52
-31.61%
-1.16
Change In Payables And Accrued Expense
0.00
0.00
0.00
+100.00%
-1.35
Change In Payable
—
—
—
-1.35
Change In Account Payable
0.00
0.00
0.00
+100.00%
-1.35
Change In Other Working Capital
0.53
—
—
—
Change In Other Current Assets
-0.31
-502.56%
0.08
-2.50%
0.08
-92.02%
1.00
Change In Other Current Liabilities
3.22
+284.27%
0.84
+707.97%
-0.14
-139.77%
0.35
Investing Cash Flow
3.04
+4385.92%
-0.07
+94.33%
-1.25
+68.64%
-4.00
Cash Flow From Continuing Investing Activities
3.04
+4385.92%
-0.07
+94.33%
-1.25
+68.64%
-4.00
Net PPE Purchase And Sale
-0.02
-10.53%
-0.02
0.00
0.00
Purchase Of PPE
-0.02
-10.53%
-0.02
0.00
0.00
Capital Expenditure
-0.02
-10.53%
-0.02
—
—
Net Investment Purchase And Sale
3.06
+5992.31%
-0.05
+95.85%
-1.25
+68.64%
-4.00
Purchase Of Investment
0.00
+100.00%
-0.05
+95.85%
-1.25
+68.64%
-4.00
Sale Of Investment
3.06
0.00
0.00
—
Net Other Investing Changes
—
—
—
—
Financing Cash Flow
10.01
+122.11%
4.50
+11162.50%
0.04
+172.73%
-0.06
Cash Flow From Continuing Financing Activities
10.01
+122.11%
4.50
+11162.50%
0.04
+172.73%
-0.06
Net Issuance Payments Of Debt
-0.20
-39.01%
-0.14
-18.49%
-0.12
-116.36%
-0.06
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
-0.20
-39.01%
-0.14
-18.49%
-0.12
-116.36%
-0.06
Long Term Debt Payments
-0.20
-39.01%
-0.14
-18.49%
-0.12
-116.36%
-0.06
Net Long Term Debt Issuance
-0.20
-39.01%
-0.14
-18.49%
-0.12
-116.36%
-0.06
Short Term Debt Issuance
—
—
—
0.00
Net Short Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
10.06
+120.06%
4.57
+18945.83%
0.02
0.00
Proceeds From Stock Option Exercised
0.14
+90.67%
0.07
-44.44%
0.14
0.00
Changes In Cash
0.20
-93.05%
2.91
+117.20%
-16.91
+28.54%
-23.67
Effect Of Exchange Rate Changes
0.08
+122.89%
-0.37
-1210.71%
-0.03
+92.96%
-0.40
Beginning Cash Position
3.72
—
—
—
End Cash Position
4.01
+7.68%
3.72
+214.79%
1.18
-93.47%
18.12
Free Cash Flow
-12.87
-732.88%
-1.54
+90.16%
-15.70
+19.97%
-19.61
Common Stock Issuance
10.06
+120.06%
4.57
+18945.83%
0.02
0.00
Issuance Of Capital Stock
10.06
+120.06%
4.57
+18945.83%
0.02
0.00
Taxes Refund Paid
-0.07
-100.85%
8.78
0.00
-100.00%
0.49
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category